Place · Level 3 · Pharmacology
GLP-1 agonists · mechanism / efficacy / real cost
Semaglutide -14.9% · Tirzepatide -20.9% · 但停药反弹 2/3 · 副作用 + 肌肉流失真实存在 · 不是奇迹, 是长期承诺
Last updated
Story path
- 1What they are · gut hormone, pharmacologizedWhat they are · gut hormone, pharmacologized
- 2Mechanism · 3 parallel pathways · centrally satiety dominatesMechanism · 3 parallel pathways · centrally satiety dominates
- 3Trial evidence · STEP 1 / SURMOUNT 1 · current pharmacologic ceilingTrial evidence · STEP 1 / SURMOUNT 1 · current pharmacologic ceiling
- 4Real cost · regain / side effects / muscle / long-term unknownReal cost · regain / side effects / muscle / long-term unknown
- 5Who should · who shouldn't · how to use correctlyWho should · who shouldn't · how to use correctly
Chapter 1
What they are · gut hormone, pharmacologized
What they are · gut hormone, pharmacologized
glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. (glucagon-like peptide-1) is a gut hormone, not a synthetic invention. Secreted by intestinal L-cells (mainly distal ileum + colon) after meals; its native half-life is only 1-2 minutes (rapidly degraded by DPP-4 enzyme).
Four native actions of GLP-1:
Insulin secretion (glucose-dependent) — only fires when glucose is high, unlike sulfonylureas which push insulin indiscriminatelyGlucagon suppression — reduces hepatic glucose outputDelayed gastric emptying — food stays in stomach longer, prolonging satietyCentral satiety — acts on hypothalamus + brainstem NTS (nucleus tractus solitarius), directly dampening appetite signals
Key pharmacological breakthroughs:
Exenatide (2005, from lizard saliva): 1st gen, twice-daily injectionLiraglutide (Victoza / Saxenda, 2010/2014): fatty-acid side chain → 13 h half-life, once-dailySemaglutide (Ozempic / Wegovy, 2017/2021): further extended → 165 h half-life, once-weekly injectionTirzepatide (Mounjaro / Zepbound, 2022/2023): dual agonist (GLP-1 + GIP), once-weekly, more potent
Indication evolution:
Originally type-2 diabetes (Ozempic / Mounjaro brand names)From 2021, FDA-approved for chronic weight management (Wegovy / Zepbound brands): BMI ≥ 30, or BMI ≥ 27 + at least 1 weight-related comorbidity (T2D / hypertension / dyslipidemia / OSA / cardiovascular disease)
Key takeaways:
This is not a new mechanism — it is pharmacological amplification of an existing human hormone, stretching half-life from 1 minute to 165 hoursNot a 'fat burner' or 'metabolic accelerator' — the core action is central satiety so you eat lessOrder of launch: diabetes first, weight management second — the weight-loss effect was observed as a 'side product' before high-dose weight-loss indications were developed
Four native actions of GLP-1:
Insulin secretion (glucose-dependent) — only fires when glucose is high, unlike sulfonylureas which push insulin indiscriminatelyGlucagon suppression — reduces hepatic glucose outputDelayed gastric emptying — food stays in stomach longer, prolonging satietyCentral satiety — acts on hypothalamus + brainstem NTS (nucleus tractus solitarius), directly dampening appetite signals
Key pharmacological breakthroughs:
Exenatide (2005, from lizard saliva): 1st gen, twice-daily injectionLiraglutide (Victoza / Saxenda, 2010/2014): fatty-acid side chain → 13 h half-life, once-dailySemaglutide (Ozempic / Wegovy, 2017/2021): further extended → 165 h half-life, once-weekly injectionTirzepatide (Mounjaro / Zepbound, 2022/2023): dual agonist (GLP-1 + GIP), once-weekly, more potent
Indication evolution:
Originally type-2 diabetes (Ozempic / Mounjaro brand names)From 2021, FDA-approved for chronic weight management (Wegovy / Zepbound brands): BMI ≥ 30, or BMI ≥ 27 + at least 1 weight-related comorbidity (T2D / hypertension / dyslipidemia / OSA / cardiovascular disease)
Key takeaways:
This is not a new mechanism — it is pharmacological amplification of an existing human hormone, stretching half-life from 1 minute to 165 hoursNot a 'fat burner' or 'metabolic accelerator' — the core action is central satiety so you eat lessOrder of launch: diabetes first, weight management second — the weight-loss effect was observed as a 'side product' before high-dose weight-loss indications were developed
药物化 · 从一分钟拉到一周
药物化的关键突破:Exenatide (2005, 蜥蜴唾液衍生): 第一代, 每日 2 次注射Liraglutide (Victoza / Saxenda, 2010/2014): 修饰脂肪酸侧链 → 半衰期 13 小时, 每日 1 次Semaglutide (Ozempic / Wegovy, 2017/2021): 进一步延长 → 半衰期 165 小时, 每周 1 次注射Tirzepatide (Mounjaro / Zepbound, 2022/2023): 双激动剂 (glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. + GIP), 每周 1 次, 效力更强
适应症 · 谁被批准用
适应症演化:最初全部为 2 型糖尿病 (Ozempic / Mounjaro 商品名)2021 起 FDA 批为慢性体重管理适应症 (Wegovy / Zepbound 商品名): BMI ≥ 30, 或 BMI ≥ 27 + 至少 1 项体重相关共病 (T2D / 高血压、血脂异常、阻塞性睡眠呼吸暂停、心血管病)
关键认知:
这不是新机制, 是人体已有激素的药物化放大 — 半衰期从 1 分钟拉到 165 小时不是燃脂药也不是代谢加速药, 核心是通过中枢饱腹让你少吃上市顺序: 糖尿病在先, 减重在后 — 因为减重效应是副产品被观察到, 才开发了高剂量减重适应症
Chapter 2
Mechanism · 3 parallel pathways · centrally satiety dominates
Mechanism · 3 parallel pathways · centrally satiety dominates
glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. receptor agonist weight-loss effects are not single-pathway — three mechanisms fire in parallel, but central satiety dominates (not metabolic alteration).
Mechanism ① Central satiety (dominant, 60-70% of weight-loss effect):
Hypothalamus (arcuate nucleus ARC) + brainstem NTS are rich in GLP-1 receptorsActivation → POMC neuron activity ↑ + AgRP neuron activity ↓ → appetite signals directly suppressedPatient subjective experience: 'I'm not interested in food anymore' / 'I'm full after a few bites' / 'I don't crave snacks'Clinical measurement: total daily energy intake drops 300-600 kcal (Blundell 2017 and others)This is why GLP-1 outperforms pure dieting — dieting is 'want to eat but resist'; GLP-1 is 'don't want to eat'. The adherence gap is enormous
Mechanism ② Delayed gastric emptying:
Gastric emptying time extends 30-70 minutesExplains early satiety + prolonged fullness 4-6 hoursRoot of side effects: food retention → nausea / reflux / bloatingSurgical anesthesia relevance: ASA 2023 recommends stopping the drug 1 week before elective surgery (aspiration risk), because delayed emptying may leave stomach contents even when fasted
Mechanism ③ Insulin + glucagon regulation (glucose improvement):
Glucose-dependent insulinotropic action — postprandial glucose peak loweredGlucagon suppression — fasting glucose loweredHbA1c reduction 1.5-2.0% (T2D patients), on par with the strongest oral hypoglycemicsWeight loss is independent of glycemic effect — non-diabetic obese patients also lose weight (this is the basis for the Wegovy / Zepbound indication)
Tirzepatide adds one more (dual GIP agonism):
GIP (glucose-dependent insulinotropic peptide) is another gut hormoneSynergy: weight loss + improved lipid metabolism + possibly better glycemic controlClinical result: tirzepatide weight-loss effect is ~40% greater than semaglutide
Key takeaways:
Dominant effect is 'you naturally eat less', not 'metabolism speeds up'Not a fat-burner — no data show resting metabolic rate increases; in fact RMR drops during weight loss (thermodynamic norm)'Inject and lose weight' is essentially 'inject and eat less' — long-term mechanism still obeys the first law of thermodynamics
Atlas reference: leptin-set-point explains why the brain pushes appetite up after natural dieting; GLP-1 effectively bypasses this defense (Sumithran 2011 classic).
Mechanism ① Central satiety (dominant, 60-70% of weight-loss effect):
Hypothalamus (arcuate nucleus ARC) + brainstem NTS are rich in GLP-1 receptorsActivation → POMC neuron activity ↑ + AgRP neuron activity ↓ → appetite signals directly suppressedPatient subjective experience: 'I'm not interested in food anymore' / 'I'm full after a few bites' / 'I don't crave snacks'Clinical measurement: total daily energy intake drops 300-600 kcal (Blundell 2017 and others)This is why GLP-1 outperforms pure dieting — dieting is 'want to eat but resist'; GLP-1 is 'don't want to eat'. The adherence gap is enormous
Mechanism ② Delayed gastric emptying:
Gastric emptying time extends 30-70 minutesExplains early satiety + prolonged fullness 4-6 hoursRoot of side effects: food retention → nausea / reflux / bloatingSurgical anesthesia relevance: ASA 2023 recommends stopping the drug 1 week before elective surgery (aspiration risk), because delayed emptying may leave stomach contents even when fasted
Mechanism ③ Insulin + glucagon regulation (glucose improvement):
Glucose-dependent insulinotropic action — postprandial glucose peak loweredGlucagon suppression — fasting glucose loweredHbA1c reduction 1.5-2.0% (T2D patients), on par with the strongest oral hypoglycemicsWeight loss is independent of glycemic effect — non-diabetic obese patients also lose weight (this is the basis for the Wegovy / Zepbound indication)
Tirzepatide adds one more (dual GIP agonism):
GIP (glucose-dependent insulinotropic peptide) is another gut hormoneSynergy: weight loss + improved lipid metabolism + possibly better glycemic controlClinical result: tirzepatide weight-loss effect is ~40% greater than semaglutide
Key takeaways:
Dominant effect is 'you naturally eat less', not 'metabolism speeds up'Not a fat-burner — no data show resting metabolic rate increases; in fact RMR drops during weight loss (thermodynamic norm)'Inject and lose weight' is essentially 'inject and eat less' — long-term mechanism still obeys the first law of thermodynamics
Atlas reference: leptin-set-point explains why the brain pushes appetite up after natural dieting; GLP-1 effectively bypasses this defense (Sumithran 2011 classic).
机制 · 胃排空慢下来
机制 ② 胃排空延迟:胃排空时间延长 30-70 分钟解释了为什么用药后早饱 + 饱腹感延长 4-6 小时副作用根源: 胃中食物滞留 → 恶心、反流、腹胀手术麻醉相关: ASA 2023 建议择期手术前停药 1 周 (避免误吸风险), 因为胃排空延迟可能导致空腹也有胃内容
机制 · 血糖那条线
机制 ③ 胰岛素 + 胰高血糖素调节 (改善血糖):葡萄糖依赖性促胰岛素 — 餐后血糖峰值下降抑制胰高血糖素 — 空腹血糖下降HbA1c 下降 1.5-2.0% (T2D 患者), 与最强口服降糖药相当减重独立于血糖效应, 即使非糖尿病肥胖者也减重 (这是 Wegovy / Zepbound 适应症的依据)
Tirzepatide 多一手 (GIP 双激动):
GIP (葡萄糖依赖性促胰岛素肽) 也是肠道激素协同效应: 减重 + 改善脂肪代谢 + 可能更好的血糖控制临床表现: tirzepatide 减重效应比 semaglutide 高约 40%
认知 · 它不是燃脂药
关键认知:主导效应是让你自然少吃, 不是让代谢变快不是燃脂药 — 没有数据显示静息代谢率上升, 实际上减重过程中 RMR 还会下降 (热力学常态)打针就瘦的本质是打针就吃少, 长期机制依然遵守热力学第一定律
参考 atlas: leptin-set-point 解释了为什么自然节食后大脑会推高食欲, glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. 等于绕过了这套防御机制 (Sumithran 2011 经典文献)
Chapter 3
Trial evidence · STEP 1 / SURMOUNT 1 · current pharmacologic ceiling
Trial evidence · STEP 1 / SURMOUNT 1 · current pharmacologic ceiling
glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. agonist weight-loss efficacy far exceeds all historic non-surgical interventions — the biggest pharmacologic breakthrough in 50 years of obesity treatment.
STEP 1 (semaglutide for weight loss) — Wilding 2021 NEJM:
Design: n=1961, BMI ≥ 30 (or ≥ 27 + comorbidity) but without diabetesIntervention: semaglutide 2.4 mg subcutaneous once weekly × 68 weeks, double-blindBoth arms received lifestyle counseling (diet + exercise)Result: semaglutide arm body-weight change -14.9% vs placebo -2.4% (P < 0.001)Patients reaching ≥ 5% / ≥ 10% / ≥ 15% weight loss: 86.4% / 69.1% / 50.5% vs 31.5% / 12.0% / 4.9%Also improved: waist / systolic BP / HbA1c / lipids / C-reactive protein: A liver protein that rises with inflammation — a common blood marker for 'is the body inflamed'. / quality-of-life scores
SURMOUNT 1 (tirzepatide for weight loss) — Jastreboff 2022 NEJM:
Design: n=2539, BMI ≥ 30 (or ≥ 27 + comorbidity), non-diabeticIntervention: tirzepatide 5 / 10 / 15 mg once weekly × 72 weeks, double-blindResult (15 mg arm): body-weight change -20.9% vs placebo -3.1% (P < 0.001)≥ 5% / ≥ 10% / ≥ 15% / ≥ 20% weight loss: 91% / 84% / 71% / 57% vs 35% / 19% / 9% / 3%First non-surgical drug to bring > half of patients to ≥ 15% weight loss — approaches sleeve gastrectomy at 1-year follow-up
Historical comparison (why this is a breakthrough):
Orlistat (Xenical / Alli, 1999): ~ -3 kg (-3%), with oily-stool side effectPhentermine (sympathomimetic): short-term (≤ 12 weeks) -3 to -5 kg, cardiovascular side effects limit long-term useLiraglutide 3.0 mg (Saxenda, 2014): ~ -8%, about half of semaglutideLifestyle (Look AHEAD T2D study) Look AHEAD 2013 NEJM: intensive lifestyle intervention at 1 year -8.6%, but long-term 4-year only -4.7% (clear regain)Bariatric surgery (Roux-en-Y / sleeve): 1 year -25 to -32%, long-term 5 year -20 to -25% (Eisenberg 2022 ASMBS/IFSO guideline)
Current pharmacologic potency ladder:
Lifestyle (intensive): -5 to -8%Orlistat / phentermine: -3 to -5%Liraglutide 3.0 mg: -8%Semaglutide 2.4 mg: -15%Tirzepatide 15 mg: -21%Bariatric surgery: -25 to -32%
Important addition: STEP-HFpEF / SELECT trials show semaglutide reduces major cardiovascular events by 20% in patients with existing cardiovascular disease — independent CV benefit beyond weight loss
Key takeaways:
Weight-loss magnitude is within ~ 5% of bariatric surgery — first non-invasive option approaching surgical efficacyBut onset requires ≥ 16 weeks, full effect ≥ 1 year — not a '3-week-results' viral productAll trials add lifestyle intervention — there is no 'lie back and inject' design
STEP 1 (semaglutide for weight loss) — Wilding 2021 NEJM:
Design: n=1961, BMI ≥ 30 (or ≥ 27 + comorbidity) but without diabetesIntervention: semaglutide 2.4 mg subcutaneous once weekly × 68 weeks, double-blindBoth arms received lifestyle counseling (diet + exercise)Result: semaglutide arm body-weight change -14.9% vs placebo -2.4% (P < 0.001)Patients reaching ≥ 5% / ≥ 10% / ≥ 15% weight loss: 86.4% / 69.1% / 50.5% vs 31.5% / 12.0% / 4.9%Also improved: waist / systolic BP / HbA1c / lipids / C-reactive protein: A liver protein that rises with inflammation — a common blood marker for 'is the body inflamed'. / quality-of-life scores
SURMOUNT 1 (tirzepatide for weight loss) — Jastreboff 2022 NEJM:
Design: n=2539, BMI ≥ 30 (or ≥ 27 + comorbidity), non-diabeticIntervention: tirzepatide 5 / 10 / 15 mg once weekly × 72 weeks, double-blindResult (15 mg arm): body-weight change -20.9% vs placebo -3.1% (P < 0.001)≥ 5% / ≥ 10% / ≥ 15% / ≥ 20% weight loss: 91% / 84% / 71% / 57% vs 35% / 19% / 9% / 3%First non-surgical drug to bring > half of patients to ≥ 15% weight loss — approaches sleeve gastrectomy at 1-year follow-up
Historical comparison (why this is a breakthrough):
Orlistat (Xenical / Alli, 1999): ~ -3 kg (-3%), with oily-stool side effectPhentermine (sympathomimetic): short-term (≤ 12 weeks) -3 to -5 kg, cardiovascular side effects limit long-term useLiraglutide 3.0 mg (Saxenda, 2014): ~ -8%, about half of semaglutideLifestyle (Look AHEAD T2D study) Look AHEAD 2013 NEJM: intensive lifestyle intervention at 1 year -8.6%, but long-term 4-year only -4.7% (clear regain)Bariatric surgery (Roux-en-Y / sleeve): 1 year -25 to -32%, long-term 5 year -20 to -25% (Eisenberg 2022 ASMBS/IFSO guideline)
Current pharmacologic potency ladder:
Lifestyle (intensive): -5 to -8%Orlistat / phentermine: -3 to -5%Liraglutide 3.0 mg: -8%Semaglutide 2.4 mg: -15%Tirzepatide 15 mg: -21%Bariatric surgery: -25 to -32%
Important addition: STEP-HFpEF / SELECT trials show semaglutide reduces major cardiovascular events by 20% in patients with existing cardiovascular disease — independent CV benefit beyond weight loss
Key takeaways:
Weight-loss magnitude is within ~ 5% of bariatric surgery — first non-invasive option approaching surgical efficacyBut onset requires ≥ 16 weeks, full effect ≥ 1 year — not a '3-week-results' viral productAll trials add lifestyle intervention — there is no 'lie back and inject' design
对照 · 跟别的办法比
glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. 这类药的减重效力远超以往所有非手术手段, 是过去 50 年减重领域最大的一次药理学突破。这是什么概念? 强化生活方式干预一年大概减 5–8% (而且往往几年内反弹掉一半), 老一代减肥药 (奥利司他、芬特明) 只有 3–5%, 而袖状胃切除这类减重手术是 -25% 到 -32%。GLP-1 第一次让一个不用开刀的选项, 逼近了手术的效果。
Chapter 4
Real cost · regain / side effects / muscle / long-term unknown
Real cost · regain / side effects / muscle / long-term unknown
Potency does not equal no cost. glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. agonists carry six real costs, and any 'miracle weight-loss drug' narrative dodges at least half of them.
Cost ① Regain after stopping (the biggest problem):
STEP 1 extension (Wilding 2022): STEP 1 patients stopped drug + lifestyle at 68 weeks, followed 52 weeksResult: ~ 2/3 of weight loss regained within 1 year of stopping — patients who had lost 17.3% regained 11.6 percentage points, net retention only -5.6%Metabolic markers (BP / lipids / HbA1c / C-reactive protein: A liver protein that rises with inflammation — a common blood marker for 'is the body inflamed'.) all reverted to near baselineMechanism: hunger hormones (leptin / ghrelin / PYY) are permanently reset after weight loss (Sumithran 2011 classic) — the brain still believes 'we should return to old weight'; stop the drug and the hunger signals returnClinical implication: GLP-1 is long-term / potentially lifelong, not a 'lose weight then stop' course
Cost ② GI side effects (70% of patients):
Nausea 44% / diarrhea 30% / vomiting 24% / constipation 24% / abdominal pain 20% (STEP 1 data)Mostly worst in first 4-8 weeks, then tolerance develops5-10% discontinue due to side effectsSevere nausea / vomiting risks: dehydration / electrolyte imbalance / kidney injuryMitigation: ① slow dose escalation (4-week intervals) ② small frequent meals ③ avoid high-fat high-fiber meals ④ avoid large single meals
Cost ③ Disproportionate muscle loss:
~ 40% of weight loss is lean mass (muscle + organs + bone) vs ~ 25-30% in traditional caloric restrictionMechanism: GLP-1 suppresses appetite → protein intake also drops + faster weight-loss rate (vs slow CR which spares lean tissue)Consequence: long-term sarcopenia → larger RMR drop → harder regain + falls / fracture risk in elderlyCountermeasures: ① protein intake ≥ 1.4-1.6 g/kg body weight/day (Longland 2016 AJCN proves high-protein preserves lean mass) ② resistance training ≥ 2×/week ③ DEXA monitoring of lean massWithout these two, GLP-1 = trading muscle for fat — long-term net negative
Cost ④ Rare but serious adverse events:
Pancreatitis (acute): rare, incidence < 0.5%, but serious and requires stoppingGallbladder issues: rapid weight loss → bile stasis → gallstone / cholecystitis risk ~ 2× higherThyroid C-cell (animal data): medullary thyroid carcinoma in rats, not confirmed in humans. MEN2 / personal history of medullary thyroid cancer = absolute contraindicationDiabetic retinopathy worsening: rapid glucose drop can short-term worsen (T2D patients need ophthalmology evaluation before starting)Surgical anesthesia aspiration risk (delayed gastric emptying noted above)
Cost ⑤ Long-term safety (> 5 years) data still limited:
Semaglutide launched 2017 (diabetes), 2021 weight-loss indication — large-scale long-term data < 8 yearsTirzepatide launched 2022 — even less long-term dataUnknowns: long-term muscle loss in elderly function / psychological dependence / long-term pancreatic & gallbladder burden / rare immune reactions
Cost ⑥ Economic cost:
US: $1000-1400/month without insurance; coverage varies — for weight-loss indication (Wegovy / Zepbound), most private insurance and Medicare do not coverChina: semaglutide entered insurance in 2024 (T2D indication only); weight-loss indication is out-of-pocket, monthly cost ~ ¥1500-2500Lifetime cumulative cost = tens of thousands of dollarsGray-market / counterfeit risk: compounded injectables / unverified channels have produced multiple serious adverse events
Summary:
This is not a 'free lunch'. It is a potent + long-term commitment + real-risk tool. Right person, huge benefit; wrong person, side effects and sarcopenia far outweigh gains.
Cost ① Regain after stopping (the biggest problem):
STEP 1 extension (Wilding 2022): STEP 1 patients stopped drug + lifestyle at 68 weeks, followed 52 weeksResult: ~ 2/3 of weight loss regained within 1 year of stopping — patients who had lost 17.3% regained 11.6 percentage points, net retention only -5.6%Metabolic markers (BP / lipids / HbA1c / C-reactive protein: A liver protein that rises with inflammation — a common blood marker for 'is the body inflamed'.) all reverted to near baselineMechanism: hunger hormones (leptin / ghrelin / PYY) are permanently reset after weight loss (Sumithran 2011 classic) — the brain still believes 'we should return to old weight'; stop the drug and the hunger signals returnClinical implication: GLP-1 is long-term / potentially lifelong, not a 'lose weight then stop' course
Cost ② GI side effects (70% of patients):
Nausea 44% / diarrhea 30% / vomiting 24% / constipation 24% / abdominal pain 20% (STEP 1 data)Mostly worst in first 4-8 weeks, then tolerance develops5-10% discontinue due to side effectsSevere nausea / vomiting risks: dehydration / electrolyte imbalance / kidney injuryMitigation: ① slow dose escalation (4-week intervals) ② small frequent meals ③ avoid high-fat high-fiber meals ④ avoid large single meals
Cost ③ Disproportionate muscle loss:
~ 40% of weight loss is lean mass (muscle + organs + bone) vs ~ 25-30% in traditional caloric restrictionMechanism: GLP-1 suppresses appetite → protein intake also drops + faster weight-loss rate (vs slow CR which spares lean tissue)Consequence: long-term sarcopenia → larger RMR drop → harder regain + falls / fracture risk in elderlyCountermeasures: ① protein intake ≥ 1.4-1.6 g/kg body weight/day (Longland 2016 AJCN proves high-protein preserves lean mass) ② resistance training ≥ 2×/week ③ DEXA monitoring of lean massWithout these two, GLP-1 = trading muscle for fat — long-term net negative
Cost ④ Rare but serious adverse events:
Pancreatitis (acute): rare, incidence < 0.5%, but serious and requires stoppingGallbladder issues: rapid weight loss → bile stasis → gallstone / cholecystitis risk ~ 2× higherThyroid C-cell (animal data): medullary thyroid carcinoma in rats, not confirmed in humans. MEN2 / personal history of medullary thyroid cancer = absolute contraindicationDiabetic retinopathy worsening: rapid glucose drop can short-term worsen (T2D patients need ophthalmology evaluation before starting)Surgical anesthesia aspiration risk (delayed gastric emptying noted above)
Cost ⑤ Long-term safety (> 5 years) data still limited:
Semaglutide launched 2017 (diabetes), 2021 weight-loss indication — large-scale long-term data < 8 yearsTirzepatide launched 2022 — even less long-term dataUnknowns: long-term muscle loss in elderly function / psychological dependence / long-term pancreatic & gallbladder burden / rare immune reactions
Cost ⑥ Economic cost:
US: $1000-1400/month without insurance; coverage varies — for weight-loss indication (Wegovy / Zepbound), most private insurance and Medicare do not coverChina: semaglutide entered insurance in 2024 (T2D indication only); weight-loss indication is out-of-pocket, monthly cost ~ ¥1500-2500Lifetime cumulative cost = tens of thousands of dollarsGray-market / counterfeit risk: compounded injectables / unverified channels have produced multiple serious adverse events
Summary:
This is not a 'free lunch'. It is a potent + long-term commitment + real-risk tool. Right person, huge benefit; wrong person, side effects and sarcopenia far outweigh gains.
数字 · 停药一年后剩多少
代价 ① 停药反弹 (最大问题):STEP 1 extension (Wilding 2022): STEP 1 患者 68 周后停药 + 停生活方式干预, 随访 52 周结果: 停药 1 年内反弹 2/3 减重量 — 原本减 17.3% 的, 反弹回去 11.6 个百分点, 净剩 -5.6%代谢指标 (血压、血脂 / HbA1c / C-reactive protein: A liver protein that rises with inflammation — a common blood marker for 'is the body inflamed'.) 全部回退到接近基线机制: leptin / ghrelin / PYY 等饥饿激素在减重后被永久重设 (Sumithran 2011 经典文献) — 大脑依然认为应该回到原体重, 药一停, 饥饿信号回来临床含义: glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. 是长期、可能终身用药, 不是瘦下来就停的疗程
副作用 · 胃肠道那一关
代价 ② 胃肠副作用 (70% 患者经历):恶心 44% / 腹泻 30% / 呕吐 24% / 便秘 24% / 腹痛 20% (STEP 1 数据)大多前 4-8 周最重, 之后耐受5-10% 患者因副作用停药严重恶心、呕吐风险: 脱水、电解质失衡、肾损伤缓解策略: 慢速加量 (4 周一档) / 小餐多餐、避免高脂高纤维餐、避免一次性大量进食
代价 · 掉的不只是脂肪
代价 ③ 肌肉流失偏高:减重中约 40% 是 lean mass (肌肉 + 内脏 + 骨), 传统能量限制饮食约 25-30%机制: glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. 抑制食欲 → 蛋白质摄入也下降 + 减重速度快 (传统 CR 慢 → 身体优先消耗脂肪)后果: 长期肌少 → 基础代谢率下降更多 → 反弹更猛 + 老年人 sarcopenia 风险 + 跌倒、骨折风险对策: ① 蛋白质摄入 ≥ 1.4-1.6 g/kg 体重/天 (Longland 2016 AJCN 证明高蛋白能保肌) ② 抗阻训练 ≥ 2 次/周 ③ DEXA 监测 lean mass不做这两件事的 GLP-1 用药 = 用肌肉换体脂, 长期得不偿失
风险 · 罕见但要认得
代价 ④ 罕见但严重的不良事件:胰腺炎 (急性): 罕见, 发病率 < 0.5%, 但严重需停药胆囊问题: 快速减重 → 胆汁淤积 → 胆结石、胆囊炎风险 ↑ ~ 2 倍甲状腺 C 细胞 (动物数据): 大鼠出现甲状腺髓样癌, 人类未证实. MEN2 / 既往甲状腺髓样癌史绝对禁忌糖尿病视网膜病变恶化: 快速血糖下降可能短期加重 (T2D 患者起用前需眼科评估)手术麻醉误吸风险 (上述胃排空延迟)
未知 · 长期数据还太短
代价 ⑤ 长期安全性 (> 5 年) 数据仍少:semaglutide 2017 上市 (糖尿病), 2021 减重适应症 — 大规模长期数据 < 8 年tirzepatide 2022 上市 — 长期数据更少未知项: 长期肌肉流失对老年功能、心理依赖、长期胰腺、胆囊负担、极少数人群的免疫反应
成本 · 这笔账要算清
代价 ⑥ 经济成本:美国: $1000-1400/月 (无医保覆盖), 医保覆盖差异大 — 减重适应症 (Wegovy / Zepbound) 多数私保和 Medicare 不覆盖中国: semaglutide 2024 进医保 (T2D 适应症), 减重适应症需自费, 月费 ~ 1500-2500 元长期用 (终生) 累计成本 = 数十万黑市、仿制品风险: 复方注射液、未经验证的渠道导致严重不良事件已有多例报告
总结:
这不是免费午餐. 是强力 + 长期承诺 + 真实风险的工具. 用对人, 收益巨大; 用错人, 副作用与肌少远超收益.
Chapter 5
Who should · who shouldn't · how to use correctly
Who should · who shouldn't · how to use correctly
glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. is neither 'inject when you want to be thin' nor 'never touch'. It is a long-term management tool on the level of antihypertensives — for the right person, used correctly, for life.
Candidates to consider (4 stacked conditions, not any one):
① BMI ≥ 30 (Asians can adjust to ≥ 28), or BMI ≥ 27 + at least 1 weight-related comorbidity: T2D / obstructive sleep apnea (OSA) / cardiovascular disease / severe hypertension / severe dyslipidemia② Already attempted ≥ 6 months of serious lifestyle intervention (diet + exercise + behavioral support) without reaching goals — not 'seeking a shortcut'③ Accepts this is long-term / potentially lifelong — psychologically and financially able to bear it④ Willing to comply: high-protein diet (≥ 1.4 g/kg/d) + resistance training (≥ 2×/week) + regular medical follow-up (every 3 months)
Not suitable / should avoid:
Healthy adults wanting to lose 5-10 kg for appearance — side-effect risk / long-term commitment / financial cost vs benefit is severely disproportionate. This group should prioritize lifestyle + resistance training + dietary structure changesUnwilling to use long-term — stopping = ~ 2/3 regain; equivalent to 'wasted 1 year of drug + side effects + thousands of dollars'Pregnant / planning pregnancy / lactating — insufficient safety data; current guidelines recommend stopping ≥ 2 months before planned pregnancyHistory of pancreatitis — risk additionMEN2 / family history of medullary thyroid cancer — absolute contraindicationSevere gastroparesis / GERD — further delayed emptying worsens symptomsHistory of eating disorders (anorexia / bulimia) — GLP-1 directly intervenes on appetite, psychological riskUnder 18 — only limited data for liraglutide 12+ / semaglutide 12+; most guidelines require strict assessment
How to use correctly (practical principles):
Slow titration: 0.25 mg → 0.5 → 1.0 → 1.7 → 2.4 mg, one step per 4 weeks — don't skip steps for faster effect, side effects will explodeAdd lifestyle: high protein + resistance + produce + alcohol limit + adequate sleep — all trials stack these; there is no 'lie flat and lose' data supportRegular monitoring: weight / BP / HbA1c / liver-kidney function / DEXA lean mass (if available) / mental health / thyroid palpationDo not stack with other weight-loss drugs (orlistat / phentermine / prescription GLP-1 + self-purchased counterfeit)Legitimate channels only: use FDA / NMPA / EMA-approved brands only; stay away from compounded injectables / 'magic formula' mixes / unverified overseas purchases
Analogy:
GLP-1 is not the 'artificial sweetener' of weight loss (eat and it cancels out)It is a long-term management tool on the level of antihypertensives — you would not tell a mild-hypertension patient 'take BP meds 3 months then stop and let it resolve'; GLP-1 is the sameTreating obesity = treating a chronic metabolic disease, not treating an 'image problem'
Atlas connections:
weight-management-foundations — understand energy balance + metabolic adaptation + behavioral pillars before weight lossleptin-set-point — explains why regain happens after stopping (brain defending weight)bariatric-surgery-truth — more aggressive option than GLP-1, with indication & cost comparisontype-2-diabetes — GLP-1's primary T2D use and the dual indication with weight lossprotein-leucine + muscle-protein-synthesis — concrete execution of muscle preservation during weight loss
Final line: This is a drug class that changed the paradigm of obesity treatment. But 'paradigm change' does not equal 'magic'. Right person, miraculous; wrong person, chronic depletion.
Candidates to consider (4 stacked conditions, not any one):
① BMI ≥ 30 (Asians can adjust to ≥ 28), or BMI ≥ 27 + at least 1 weight-related comorbidity: T2D / obstructive sleep apnea (OSA) / cardiovascular disease / severe hypertension / severe dyslipidemia② Already attempted ≥ 6 months of serious lifestyle intervention (diet + exercise + behavioral support) without reaching goals — not 'seeking a shortcut'③ Accepts this is long-term / potentially lifelong — psychologically and financially able to bear it④ Willing to comply: high-protein diet (≥ 1.4 g/kg/d) + resistance training (≥ 2×/week) + regular medical follow-up (every 3 months)
Not suitable / should avoid:
Healthy adults wanting to lose 5-10 kg for appearance — side-effect risk / long-term commitment / financial cost vs benefit is severely disproportionate. This group should prioritize lifestyle + resistance training + dietary structure changesUnwilling to use long-term — stopping = ~ 2/3 regain; equivalent to 'wasted 1 year of drug + side effects + thousands of dollars'Pregnant / planning pregnancy / lactating — insufficient safety data; current guidelines recommend stopping ≥ 2 months before planned pregnancyHistory of pancreatitis — risk additionMEN2 / family history of medullary thyroid cancer — absolute contraindicationSevere gastroparesis / GERD — further delayed emptying worsens symptomsHistory of eating disorders (anorexia / bulimia) — GLP-1 directly intervenes on appetite, psychological riskUnder 18 — only limited data for liraglutide 12+ / semaglutide 12+; most guidelines require strict assessment
How to use correctly (practical principles):
Slow titration: 0.25 mg → 0.5 → 1.0 → 1.7 → 2.4 mg, one step per 4 weeks — don't skip steps for faster effect, side effects will explodeAdd lifestyle: high protein + resistance + produce + alcohol limit + adequate sleep — all trials stack these; there is no 'lie flat and lose' data supportRegular monitoring: weight / BP / HbA1c / liver-kidney function / DEXA lean mass (if available) / mental health / thyroid palpationDo not stack with other weight-loss drugs (orlistat / phentermine / prescription GLP-1 + self-purchased counterfeit)Legitimate channels only: use FDA / NMPA / EMA-approved brands only; stay away from compounded injectables / 'magic formula' mixes / unverified overseas purchases
Analogy:
GLP-1 is not the 'artificial sweetener' of weight loss (eat and it cancels out)It is a long-term management tool on the level of antihypertensives — you would not tell a mild-hypertension patient 'take BP meds 3 months then stop and let it resolve'; GLP-1 is the sameTreating obesity = treating a chronic metabolic disease, not treating an 'image problem'
Atlas connections:
weight-management-foundations — understand energy balance + metabolic adaptation + behavioral pillars before weight lossleptin-set-point — explains why regain happens after stopping (brain defending weight)bariatric-surgery-truth — more aggressive option than GLP-1, with indication & cost comparisontype-2-diabetes — GLP-1's primary T2D use and the dual indication with weight lossprotein-leucine + muscle-protein-synthesis — concrete execution of muscle preservation during weight loss
Final line: This is a drug class that changed the paradigm of obesity treatment. But 'paradigm change' does not equal 'magic'. Right person, miraculous; wrong person, chronic depletion.
适合 · 四个条件要同时成立
适合考虑的人 (4 个条件叠加, 不是任一):① BMI ≥ 30 (亚洲人 ≥ 28 可适当下调), 或 BMI ≥ 27 + 至少 1 项体重相关共病: T2D / 阻塞性睡眠呼吸暂停 (OSA) / 心血管病、严重高血压、严重血脂异常② 已认真尝试 ≥ 6 个月的生活方式干预 (饮食 + 运动 + 行为支持) 未达目标, 而非想走捷径③ 接受这是长期、可能终身用药 — 心理上和经济上都能承担④ 愿意配合: 高蛋白饮食 (≥ 1.4 g/kg/d) + 抗阻训练 (≥ 2×/周) + 定期医疗随访 (每 3 月 1 次)
禁忌 · 这些人别用
不适合、应避免的人:想减 5-10 kg 改善形象的健康成人 — 副作用风险、长期承诺、经济成本 vs 收益严重不成比例. 这部分人应优先生活方式 + 力量训练 + 饮食结构调整不愿长期用药 — 停药即反弹 2/3, 等于白吃 1 年药 + 副作用 + 几万块怀孕、计划怀孕、哺乳期 — 妊娠安全数据不足, 当前指南建议计划怀孕前停药 ≥ 2 个月既往胰腺炎史 — 风险叠加MEN2 / 髓样甲状腺癌家族史 — 绝对禁忌严重胃轻瘫、胃食管反流 (GERD) — 胃排空进一步延迟会加重症状进食障碍 (神经性厌食、暴食) 病史 — glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. 直接干预食欲, 心理风险18 岁以下 — 仅 liraglutide 12+ / semaglutide 12+ 有有限数据, 大多数指南需要严格评估
实操 · 怎么用对
怎么用对 (实操原则):缓慢加量: 0.25 mg → 0.5 → 1.0 → 1.7 → 2.4 mg, 每 4 周 1 档 — 不要为了快效力跳档, 副作用会爆配合生活方式: 高蛋白 + 抗阻 + 蔬果 + 限酒 + 充足睡眠 — 试验都叠加这些, 没有躺平减肥的数据支持定期监测: 体重、血压 / HbA1c / 肝肾功能 / DEXA lean mass (有条件) / 心理状态、甲状腺触诊不与其他减肥药叠加 (orlistat / phentermine / 处方 glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. + 自购仿制品)正规渠道: 仅用 FDA / NMPA / EMA 批准的品牌, 远离仿制注射液、复方魔术粉、海外代购未经验证的产品
延伸 · 接着读什么
相连的话题:weight-management-foundations — 减重前必先理解能量平衡 + 代谢适应 + 行为支柱leptin-set-point — 解释为什么停药反弹 (大脑防御体重)bariatric-surgery-truth — 比 glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. 更激进的选项, 适应症与代价对比type-2-diabetes — GLP-1 对 T2D 的主用途与减重的双重适应症protein-leucine + muscle-protein-synthesis — 减重期保肌的具体执行
最后一句: 这是一类改变了肥胖治疗范式的药物. 但改变范式不等于魔法. 给对人, 是奇迹; 给错人, 是慢性消耗.
References · 8
- Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP-1). New England Journal of Medicine, 384(11), 989-1002. 10.1056/NEJMoa2032183
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205–216. 10.1056/NEJMoa2206038
- Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011). Long-term persistence of hormonal adaptations to weight loss. The New England Journal of Medicine, 365(17), 1597–1604. 10.1056/NEJMoa1105816
- The Look AHEAD Research Group. (2013). Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. The New England Journal of Medicine, 369(2), 145–154. 10.1056/NEJMoa1212914
- Eisenberg, D., Shikora, S. A., Aarts, E., Aminian, A., Angrisani, L., Cohen, R. V., De Luca, M., Faria, S. L., Goodpaster, K. P. S., Haddad, A., Himpens, J. M., Kow, L., Kurian, M., Loi, K., Mahawar, K., Nimeri, A., O'Kane, M., Papasavas, P. K., Ponce, J., … Kothari, S. N. (2022). 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for metabolic and bariatric surgery. Surgery for Obesity and Related Diseases, 18(12), 1345–1356. 10.1016/j.soard.2022.08.013
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine, 389(24), 2221-2232. In 17,604 adults with overweight/obesity and established cardiovascular disease but without diabetes, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% (HR 0.80; 6.5% vs 8.0%). 10.1056/NEJMoa2307563
- Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., Wadden, T. A., Wharton, S., Yokote, K., & Kushner, R. F. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. 10.1111/dom.14725
- Longland, T. M., Oikawa, S. Y., Mitchell, C. J., Devries, M. C., & Phillips, S. M. (2016). Higher compared with lower dietary protein during an energy deficit combined with intense exercise promotes greater lean mass gain and fat mass loss: A randomized trial. American Journal of Clinical Nutrition, 103(3), 738–746. 10.3945/ajcn.115.119339